Fig. 1

Kaplan-Meier survival curves demonstrating the effect of ANCA status at the time of switching to maintenance therapy on all patients (a), and patients who were initially either PR3-ANCA-positive (b) or MPO-ANCA-positive (c). The numbers remaining at risk in the ANCA-positive and ANCA-negative groups at each time point are shown below the appropriate survival curve. ANCA anti-neutrophil cytoplasm antibodies, MPO, myeloperoxidase, PR3 proteinase 3